drugset / Trial / NCT01326546

Therapeutic Hepatitis B Vaccine (Mimogen-based) Joint Entecavir in Treating Chronic Hepatitis B Patients

NCT01326546

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose is to evaluate efficacy and safety of therapeutic hepatitis B virus (HBV) vaccine (mimogen-based)) Joint entecavir treatment in chronic hepatitis B patients.

Timeline

Start
2010-06
Primary completion
2014-01
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Entecavir Small molecule 0.5 mg Oral
Subject εPA-44 Vaccine 900 ug